Next-Generation IRAK4 Degraders for Personalized MYD88-Mutant B-Cell Lymphoma Treatment

A paradigm-shifting approach to treating MYD88-mutant B-cell lymphomas, combining IRAK4 degraders with CRISPR-Cas9 genome editing, personalized neoantigen-based vaccines, and advanced biomarker prediction and real-time monitoring.

The original patent's IRAK4 degraders have limitations in achieving precise, targeted modification of the MYD88 gene in cancer cells. The new inventive concept addresses this limitation by integrating CRISPR-Cas9 genome editing, enabling simultaneous degradation of IRAK4 and editing of the MYD88 gene, and providing a more effective and personalized treatment approach.

The new inventive concept comprises a system for treating MYD88-mutant B-cell lymphomas, utilizing a combinatorial therapeutic regimen of IRAK4 degraders and CRISPR-Cas9 genome editing. This approach enables precise, targeted modification of the MYD88 gene in cancer cells, enhancing treatment efficacy. Additionally, the concept includes a method for generating personalized neoantigen-based vaccines, using IRAK4 degraders to enhance immunogenic cell death and stimulate an anti-tumor immune response. A composition of matter comprising a fusion protein of IRAK4 and a CRISPR-Cas9 enzyme is also disclosed, allowing for simultaneous degradation of IRAK4 and editing of the MYD88 gene. Furthermore, the concept encompasses a method for predicting the efficacy of IRAK4 degraders in treating MYD88-mutant B-cell lymphomas, using machine learning algorithms and multi-omics data integration to identify biomarkers of response. A system for in vivo monitoring of IRAK4 degradation and MYD88 gene editing in real-time, using a nanoparticle-based imaging platform and a CRISPR-Cas9 genome editing system, is also included.

The new claims introduce a novel combination of IRAK4 degraders with CRISPR-Cas9 genome editing, personalized neoantigen-based vaccines, and advanced biomarker prediction and real-time monitoring, which is not obvious from the original patent. The integration of these technologies provides a paradigm-shifting approach to treating MYD88-mutant B-cell lymphomas.

Alternative embodiments of the inventive concept could include the use of different genome editing systems, such as base editing or prime editing, or the integration of additional therapeutic modalities, such as checkpoint inhibitors or CAR-T cell therapy. Variations of the concept could also include the use of different types of IRAK4 degraders or the development of new biomarkers for predicting treatment response.

The new inventive concept has significant commercial potential in the treatment of MYD88-mutant B-cell lymphomas, with a target market of pharmaceutical companies, biotechnology firms, and research institutions. The concept's personalized approach and advanced biomarker prediction capabilities could lead to improved treatment outcomes and increased market share.